- There are differences in plasma PUFA and OXL seen in HIS, independent of obesity.
- In NAFL, HIS had lower plasma LC-PUFA, independent of histological severity.
- Compared to CAU, HIS with NASH had lower arachidonic acid derived OXLs.
- Compared to CAU, HIS with NASH showed lower LOX and up-regulated sEH pathway(s).
- Plasma OXL profiles can discriminate between HIS and CAU with NASH.

Title: **Plasma oxylipin profile discriminates ethnicities in subjects with Non-alcoholic**

steatohepatitis: An exploratory analysis

- 3 **Authors:** Tagreed A. Mazi^{1,2}, Kamil Borkowski³, Oliver Fiehn³, Christopher L. Bowlus⁴, Souvik Sarkar⁴,
- 4 Karen Matsukuma⁵, Mohamed R. Ali⁶, Dorothy A. Kieffer⁴, Yu-Jui Y. Wan⁵, Kimber L. Stanhope⁷, Peter
- 5 J. Havel^{1,7}, John W. Newman^{1,3,8}, Valentina Medici^{4*}
-

Author Affiliations:

- 1. Department of Nutrition, University of California Davis, 3135 Meyer Hall, One Shields Avenue, Davis, CA 95616, USA
- 2. Department of Community Health Sciences-Clinical Nutrition, College of Applied Medical Sciences,
- King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia; e-mail: [tmazi@ksu.edu.sa](mailto:tmazi.20@gmail.com)
- 3. West Coast Metabolomic Center, Genome Center, University of California-Davis, Davis, CA 95616, USA
- 4. Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of
- California Davis, 4150 V Street, Suite 3500 Sacramento, CA 95817, USA
- 5. Department of Pathology and Laboratory Medicine, University of California-Davis, Sacramento, CA
- 95817, USA
- 6. Department of Surgery, University of California, Davis, 2221 Stockton Boulevard, Cypress Building,
- Sacramento, CA 95817, USA
- 7. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
- 8. United States Department of Agriculture-Agriculture Research Service-Western Human Nutrition
- Research Center, Davis, CA 95616, USA
-
- ***Corresponding author**
- Valentina Medici M.D., F.A.A.S.L.D.
- University of California, Davis
- Department of Internal Medicine
- Division of Gastroenterology and Hepatology

- 4150 V Street, Suite 3500
- Sacramento, CA 95817
- Office: 916-734-3751, Fax: 916-734-7908
- Email: vmedici@ucdavis.edu
- **Short Title: Ethnicity and lipidomic profile in non-alcoholic fatty liver**
- **Word count**: 4763 words (excluding abstract, references, and figure legends)
- **Number of Figures**: 3
- **Number of Tables**: 2

Abstract (252 words**)**

Keywords

Hispanic, Caucasian, Non-alcoholic steatohepatitis, Lipidomic, Oxylipins, Endocannabinoids.

Abbreviations

- **0-NASH -** NASH-free; **CAU -** Caucasian; **COX -**Cyclooxygenases; **CYP -** Cytochrome P450; **eCBs -**
- Endocannabinoids; **FADS** Fatty acid desaturases; **FC -** Fold change; **FDR -**False discovery rate; **HC -**
- Healthy control; **HIS -** Hispanic; **LOOCV** leave- one-out cross validation**; LOX -** Lipoxygenases **NAFL**
- **-**Steatosis; **NAFLD -** Non-alcoholic fatty liver disease; **NAS -** The NAFLD Activity Score; **NASH -**Non-
- alcoholic steatohepatitis; **n-3 PUFA -** Omega−3 polyunsaturated fatty acids; **n-6 PUFA -** Omega−6
- polyunsaturated fatty acids; **NASH-CRN -** The NASH Clinical Research Network; **OXLs -** Oxylipins;
- **PCA -** Principal component analysis; **PLS-DA -** Partial least square-discriminant analysis; **PUFA -**
- Polyunsaturated fatty acids; **sEH -** Soluble epoxide hydrolases; **SPMs -** Specialized pro-resolving
- mediators; **SNP -** single nucleotide polymorphisms; **VIP -** Variable importance in projection; **Δ-5**
- **desaturase -** Delta fatty acid desaturase-5.

1. Introduction

2. Subjects and methods

2.1. Subjects and samples

 All subjects self-reported ethnicity as either HIS or CAU. HC subjects (*n* =22) were recruited via public posts. Plasma and liver samples form bariatric surgery patients with medically complicated obesity were retrieved from the biobank repository of the Division of Gastroenterology and Hepatology, UC Davis Medical Center. The primary cohort (*n* =18) consisted of subjects with NAFL and various degrees of necroinflammation. Only subjects with NASH were included in the secondary analysis (*n* =9) and this cohort was expanded with prospectively collected subjects diagnosed with NASH (*n* =20). Subject inclusion and exclusion criteria and details on data collection are described elsewhere [\[25\]](#page-25-0). Briefly, plasma samples were collected preoperatively, and liver tissue samples were collected by biopsy performed during bariatric surgery. Liver histopathological evaluations were performed in a blinded fashion in the UC Davis Medical Center Department of Pathology. Samples were scored according to the NASH Clinical Research Network (NASH-CRN) histology system, The NAFLD Activity Score (NAS) 127 and fibrosis scores were calculated [\[26\]](#page-25-1). NASH diagnosis was determined using a diagnostic algorithm based on the semi-quantitative scoring of steatosis, inflammation, and fibrosis [\[27\]](#page-25-2). All subjects were consented and the Institutional Review Board at the University of California, Davis approved the study protocol (# 856052).

2.2. Targeted lipidomic analysis

 Plasma quantitative lipidomic profiling of PUFAs, OXLs and NAEs was performed by ultra- high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-135 MS/MS), as previously described [\[28\]](#page-25-3). Briefly, plasma samples were enriched with deuterated surrogates,

2.4. Statistical analysis

- Partial least square-discriminant analysis (PLS-DA) was performed to discriminate ethnicities in NASH
- 182 subjects with leave- one-out cross validation (LOOCV) [$\frac{32}{2}$]. An R² and Q² > 0.5 are acceptable values to
- indicate reliability of the model in explaining differences between groups [\[33\]](#page-25-8). A variable importance in
- projection (VIP) score of >1.0 was set as a threshold for variable selection. To check any effect of
- advanced fibrosis, we repeated the analysis after excluding subjects with fibrosis grade 3 and 4 (*n* =3 HIS
- and n =4 CAU).

3. Results

3.1. Subject characteristics

 The clinical and histological features of NAFL subjects from the primary cohort are presented in 190 Table 1. The mean age was 47 ± 15 and 43 ± 14.2 in NAFL-HIS and HC-HIS groups, respectively; 50 ± 1.5 191 18 and 44 ± 12 in NAFL-CAU and HC-CAU, respectively (n.s). In HIS, the mean BMI was 46 ± 6 in 192 NAFL and 26 ± 2.4 in HC (*p*-value <0.05). In CAU, the mean BMI was 42 ± 8 in NAFL and 25 ± 3 in 193 HC (*p*-value <0.05). Within NAFL group, the mean NAS score was 3.2 ± 2.6 and 2.8 ± 1.4 for HIS and CAU, respectively (n.s). No difference in clinical and histological parameters was found between 195 ethnicities. In subjects with NASH compared to 0-NASH, the mean NAS score was 4.8 ± 1.7 and 4 ± 1 for HIS and CAU, respectively (n.s) (data not shown). The secondary cohort included NASH subject with various degrees of necroinflammation and fibrosis (Table 2). When comparing NASH-HIS and NASH-CAU, no difference was found with BMI and 199 other clinical and histological parameters. The mean NAS score was 5.1 ± 2 and 5.1 ± 1.3 for NASH-HIS 200 and NASH-CAU, respectively (n.s).

3.2. Ethnicity-related alterations in plasma PUFAs and lipid mediator profiles characterize NAFL

We examined differences in plasma fatty acids and lipid mediators between NAFL and HC

(Figure 1 and Table S2). Compared to corresponding HC, 25 (38% of total detected) and 7 (11%) lipid

levels were found different in NAFL-HIS and NAFL-CAU, respectively (FDR-adjusted *p* <0.2).

Ethnicity-specific changes observed in NAFL, with interaction ethnicity x NAFL, include 8 lipids (15%)

- and 2 enzymatic ratios (raw *p-*Interaction <0.05) but did not survive FDR-correction (*q* =0.2). As NAFL-
- HIS presented with more NASH and fibrosis, and to rule out any effect of histological severity on the

 differences observed between ethnicities, the analysis was repeated on a subset of histology-matched subjects (Table S3). As a result, 12 lipids (19%) and one enzymatic ratio were found altered (raw *p-*Interaction <0.05), with 3 lipids (i.e., α-linolenic, linoleic acids, and 9-HpODE) surviving FDR

correction.

 When compared to HC, there were overlapping differences seen in NAFL for both ethnicities as well as ethnicity-specific differences (Figure 1). In both ethnicities, NAFL showed higher levels of several eCBs derived from PUFA and other fatty acids. The 18 carbon (C18) PUFAs, α-linolenic and linoleic acids showed similar higher trend with higher levels of downstream fatty acid alcohols, hydroperoxide, ketones, epoxides, and vicinal diols. Specific to NAFL-HIS, there were differentially higher levels of linoleic acid-triols (i.e., TriHOMEs; raw *p-*Interaction <0.05). On histology-matched analysis, a higher TriHOMEs and linoleic acid epoxide, 12(13)-EpOME, were found significant (raw *p-* Interaction <0.05). Of note, the n-6 to n-3 ratio was higher, however, with no ethnicity x NAFL 221 interaction. In NAFL-CAU, there was differentially higher α -linolenic and linoleic acid and its hydroperoxide, 9-HpODE (raw *p-*Interaction <0.05). On histology adjustment analysis these lipids retained significance with linoleic acid, and 9-HpODE passing the FDR- threshold. The 20 carbon (C20) and longer chain PUFAs (LC-PUFA), showed opposite trends with higher levels in NAFL-CAU and lower in NAFL-HIS. The ratio of docosahexaenoic/ eicosapentanoic + α-linolenic acids was found lower in both ethnicities (FDR-adjusted *p*-value). In HIS, arachidonic acid- derived alcohols, ketones, thromboxane were higher, however, with no interaction (ethnicity x NAFL). Docosahexaenoic acid and its vicinal diol, 19,20-DiHDoPA, levels were differentially lower (raw *p-* Interaction <0.05) with tendency shown for lower eicosapentanoic acid. On histology-matched analysis, lower levels of these lipids were found significant (raw *p-*Interaction <0.05). Specific to CAU, there was differentially higher arachidonic acid and its vicinal diol, 14,15-DiHETrE that remained significant after

3.5. Plasma OXLs profile discriminate between ethnicities with NASH

 A supervised PLS-DA was performed including all profiled lipids to examine if plasma OXLs profile can discriminate between ethnicities with NASH. The model demonstrated separation between HIS and CAU with 22 (49%) contributing lipids having VIP>1. This indicates differences in OXLs 281 profile characterizes HIS and CAU with NASH (Figure S4 and Table S5). The $O²$ and $R²$ for the model were 0.62 and 0.72, respectively, indicating a fair reliability of the model. Of note, an overlap between ethnic groups was observed and subjects within this area shared advanced fibrosis (grade 3 and 4), indicating that HIS and CAU subjects with NASH and advanced fibrosis share similar plasma OXLs profile. Also, it suggests that advanced fibrosis may be attenuating the multivariate model. Therefore, we repeated the analysis after excluding subjects with advance fibrosis (Figure 3 and Table S5). As a result, the model exhibited complete separation between ethnicities in NASH with 20 (44%) lipids contributing 288 to this separation (VIP>1.0). The Q^2 , R^2 were 0.99 and 0.98, respectively, indicating optimal prediction and reliability of the multivariate model. In subjects with NASH and mild to moderate fibrosis, OXLs profiles showed opposite direction 291 of change between ethnicities in some arachidonic acid-derived mediators, with TXB₂, 15-Keto PGE₂, 5- HETE and 5,6-DiHETrE being lower in HIS compared to CAU. Many OXLs derived via LOX pathway and/or auto-oxidative routes were lower in NASH-HIS, including TriHOMEs, 13-KODE, 9-KODE, 13- HOTE, 9-HOTE, and 5-HETE. Some CYP-derived OXLs were lower in NASH-HIS, as 9(10)-EpOME, 12(13)-EpOME and 12(13)-EpODE. Multiple sEH enzymatic indices were found higher in NASH-HIS, compared to NASH-CAU, including 12,13-DiHOME/12(13)-EpOME; 9,10-DiHOME/9(10)-EpOME; 297 17_18-DiHETE/17(18)-EpETE along with higher levels of the vicinal diol, 14,15-DiHETrE. These findings further confirm lower arachidonic acid OXLs in HIS with NASH, which are also characterized

- 299 by lower LOX and higher sEH derived lipid mediators compared to CAU. They also indicate that plasma
- 300 OXL profiles can discriminate between ethnicities in NASH.

4. Discussion

 This study is the first to examine targeted plasma PUFAs, OXLs, and eCBs profiles with regards to ethnicity in a group of HIS and CAU subjects with obesity and biopsy-diagnosed NAFL and NASH. Our findings indicate that: 1) NAFL and NASH are characterized by ethnicity-related differences in plasma PUFA profiles, independent of histological severity; 2) Ethnicity-related differences in plasma OXLs profiles characterize NASH, independent of histological scores; 3) Plasma PUFA profile is altered in apparently healthy HIS, independent of obesity. The hepatic and serum/plasma PUFA profiles are dysregulated in NAFLD [\[14-18\]](#page-24-11). Our results expand on these findings and show ethnicity-related differences in plasma PUFA profile in NAFL and 310 NASH. With NAFL, both ethnicities showed higher α -linolenic and linoleic acid levels, which were pronounced in CAU but not in HIS. This can be attributed to differences in the levels of these PUFAs in lean and healthy subjects, with HIS having higher levels compared to their CAU counterpart. There was also a divergence in LC-PUFA profiles between ethnicities. CAU showed higher levels mainly affecting arachidonic acid, while HIS displayed lower levels mainly affecting docosahexaenoic and eicosapentanoic acids. Consistent trends were shown with the progression from 0-NASH to NASH with arachidonic almost reaching significance (*p-*Interaction =0.07). This is in line with our previous untargeted profiling in NAFL done on the same subjects showing higher C18-PUFAs in CAU, and a trend for lower LC-PUFA with tendencies shown for docosahexaenoic and eicosapentanoic acids in HIS [\[25\]](#page-25-0). The lack of significant difference in LC-PUFA in our previous analysis may be due to the semi- quantitative nature and the clustering statistical approach. Also in agreement with our current finding is the lower serum/plasma docosahexaenoic and eicosapentanoic levels reported in obese HIS, compared to non-HIS [\[34,](#page-25-9) [35\]](#page-25-10). Together, this implies diminished plasma LC-PUFA characterizes obese HIS with NAFL and NASH. As dietary intake affects PUFA circulating and tissue levels [\[36\]](#page-25-11), the ethnicity-

 Evidence from animal studies indicates a role for LOX pathways in NAFL and inflammation [\[45,](#page-26-5) [46\]](#page-26-6). LOX pathways lead to the synthesis of fatty acid alcohols, ketones, hydroperoxides, and the specialized pro-resolving mediators (SPMs). With exceptions, n-6 PUFA derived alcohols are pro- inflammatory [\[8\]](#page-24-5). Under oxidative stress, PUFAs can also undergo auto oxidation to form alcohols, ketones, hydroperoxides [\[9\]](#page-24-6). Previous studies reported higher LOX and auto-oxidation metabolites in NAFL and increased arachidonic acid metabolites via LOX with the progression to NASH [\[16,](#page-24-12) [20,](#page-24-16) [21,](#page-25-15) [47\]](#page-26-7). In our results, compared to control groups, NAFL and NASH in both ethnicities presented higher alcohols and ketones derived from C18-PUFAs, indicating an upregulated LOX pathway(s). In NAFL, we observed a positive correlation between some fatty acid alcohols and the oxidative stress markers, F2- isoprostanes and 9-HETE (Table S6), implying a contribution of non-enzymatic auto-oxidation. Interestingly, our secondary analysis showed many LOX derived OXLs being higher in NASH-CAU compared to NASH-HIS, with a similar trend found for the oxidative stress marker, 9-HETE (VIP=0.98). Together, these indicate that while LOX and oxidative pathways are upregulated with NAFL in both ethnicities, the magnitude of these alterations is lesser in HIS with NASH, compared to CAU. Based on this finding, we reasoned that LOX, and possibly oxidative stress, may be pivotal for NASH severity in CAU but not in HIS. CYP enzymes catalyze the synthesis of fatty acids epoxides and alcohols. With some exceptions,

 fatty acid alcohols are pro-inflammatory and epoxides are anti-inflammatory, transient and rapidly hydrolyzed by the action of sEH to form inactive or less active vicinal diols [\[8,](#page-24-5) [48\]](#page-26-8). A role for sEH in NAFLD progression is indicated by animal studies, showing that sEH inhibition improves NAFL, NASH and fibrosis [\[48\]](#page-26-8). In subjects with NASH, compared to NAFL, arachidonic acid derived vicinal diols are higher [\[20\]](#page-24-16). Our results show, with the progression to NASH, an ethnicity-dependent opposite trend for vicinal diols derived from C18-PUFA, which were higher in HIS and lower in CAU. Some of these

vicinal diols and sEH enzymatic indices showed interaction (ethnicity x NASH) and were found higher in

- NAHS-HIS and lower in NASH-CAU, compared corresponding 0-NASH. This may suggest higher
- activity of sEH in NASH-HIS. Our secondary analysis also shows higher ratios of multiple sEH
- enzymatic indices in HIS compared to CAU, and lower C18-PUFA epoxides possibly due higher
- hydrolysis rate. NASH-CAU showed higher levels of many PUFA epoxides, compared to NASH-HIS,
- indicating upregulated CYP pathway(s) and/or less hydrolysis. Together, our finding highlights ethnicity-
- related differences in sEH activity that was higher in HIS with NASH.

Extensive evidence from animal studies indicates a role for eCB system in NAFL, mitochondrial

dysfunction and inflammation and fibrosis [\[49,](#page-26-9) [50\]](#page-26-10). In NAFL, both ethnicities had higher levels of several

eCBs. However, many eCBs were higher in CAU and lower in HIS with the progression to NASH,

compared to corresponding 0-NASH (raw *p-*Interaction <0.05). We also observed levels of the oleic acid-

derived mediators N-oleoyl glycine, and oleoylethanolamide. These observations could not be examined

in our secondary analysis as we detected limited numbers of eCBs and did not profile for fatty acids.

Nevertheless, this may indicate ethnicity-related variations in eCBs profiles and oleic acid metabolism

with NAFLD in HIS that need to be further examined.

 The observed ethnicity-related alterations may be relevant to NAFLD severity. Eicosapentaenoic and docosahexaenoic acids modulate hepatic [fatty acid oxidation,](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/beta-oxidation) *de novo* lipogenesis, redox balance and inflammation via direct interaction with nuclear receptors and transcription factors [\[51\]](#page-26-11). These LC- PUFAs are also precursors to potent SPMs which drive inflammatory resolution [\[8\]](#page-24-5). Also, the proinflammatory cascade of arachidonic acid via COX is necessary for the biosynthesis of SPMs and initiating inflammatory resolution [\[11,](#page-24-8) [52\]](#page-26-12). Therefore, a diminished level of these PUFAs may abolish anti-steatogenic and anti-inflammatory mechanisms. Likewise, a higher sEH activity may result in deactivation of anti-inflammatory PUFA epoxides [\[8,](#page-24-5) [48\]](#page-26-8). Interestingly, our findings suggest that

 upregulated LOX pathway(s) may be imperative to NASH severity in CAU with a lesser extent in HIS. Collectively, we postulate that the observed ethnicity-related changes translate to the more advanced NASH histological presentation seen in HIS. Of note, these changes are independent of fibrosis or NAS scores, in fact, histology adjustment resulted in stronger differences in both analyses, implying that subjects with advanced fibrosis may share similar lipidomic profile.

 Our findings have clinical/diagnostic implications. The stage of liver fibrosis in NASH is critical to guide decisions on therapy [\[53\]](#page-26-13). Given that liver biopsy is subjected to risks and limitations, there is an ongoing search for noninvasive biomarker for NAFLD [\[54\]](#page-26-14). Several OXLs derived from arachidonic acid were shown to predict liver histological features. For example, NASH was characterized by a stepwise increase in 5- and 15-HETE; PGE2; and some vicinal diols [\[16,](#page-24-12) [20\]](#page-24-16). While our findings in NASH-CAU show trends consistent with current literature, findings in HIS indicate otherwise. Ethnicity-related differences in plasma metabolomic profile have been reported before in Alzheimer's disease and bladder cancer [\[55,](#page-26-15) [56\]](#page-26-16). Based on our finding, we propose that ethnicity-specific plasma signature may characterize NASH. On another note, clinical evidence supports a role of eicosapentaenoic and docosahexaenoic acids supplementation in improving NAFL and its risk factors [\[57,](#page-26-17) [58\]](#page-27-0). Also, there is growing data on the utility of sEH inhibitors in NASH treatment with sEH inhibitors entering clinical 409 trials [\[48,](#page-26-8) [59,](#page-27-1) [60\]](#page-27-2). Therefore, evaluating these interventions for the treatment of NASH, particularly in the HIS population seems warranted.

 This "proof-of-concept" analysis is based on a small, single-center study. The limited sample size may have compromised the correction for multiple testing in the primary analysis. However, findings from the secondary analysis were consistent and the multivariate model is validated for overfitting and predictability. Other strengths include subjects were biopsy-characterized and analysis was adjusted for BMI and histology. In conclusion, we performed targeted lipidomic profiling for PUFAs and related lipid

- mediators with regards to ethnicity. Results show ethnicity-related divergence in LC-PUFA and
- downstream OXLs profiles with NAFL and NASH progression, independent of histological scores. Our
- secondary analysis indicates that in NASH and compared to CAU, HIS are characterized by lower levels
- of arachidonic acid derived OXLs, downregulated LOX with an upregulated sEH pathway(s). The
- implications of these differences on the disparity reported in NAFLD rate and severity are not clear but
- worth further investigations. Our findings suggest ethnicity-specific lipidomic signature may characterize
- NASH. Although preliminary, these novel observations support the need for larger validation studies.

5. Data Availability Statement:

[\(http://www.metabolomicsworkbench.org\)](http://www.metabolomicsworkbench.org/), study ID numbers (ST000977 and ST001845).

6. Conflict of interest:

V.M. serves on the Advisory Board of Alexion Pharmaceuticals.

7. Author Contributions:

- Original draft writing, T.A.M.; Draft editing, T.A.M., V.M., K.B., J.W.N., Formal analysis and
- visualization, T.A.M., K.B; Methodology, T.A.M, V.M., O.F., D.K, K.M and Y.Y.W.; Investigation,
- T.A.M, K.M.; Resources, V.M., O.F., S.S., K.L.S., P.J.H. and M.A.; Funding Acquisition- V.M., J.W.N.

and P.J.H.

8. Funding:

- This work was funded by The National Institutes of Health (NIH)-West Coast [Metabolomic](https://www.sciencedirect.com/topics/medicine-and-dentistry/metabolomics) Center
- (WCMC) grant number U24 DK097154, by R01 DK104770 (to V.M.), by 1R01 HL09133 (to P.H.)
- and 1R01 HL107256 (to P.H.). Additional fund was provided by The United States Department of
- Agriculture (USDA) project [2032-51530-025-00D](https://www.sciencedirect.com/science/article/pii/S0891584921003890?via%3Dihub#gs2) (to J.W.N). The USDA is an equal opportunity
- provider and employer. The content is exclusively the responsibility of the authors and does not represent

the official views of the NIH, the WCMC or the USDA.

9. References

- 1. Younossi, Z.M., et al., *Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes.* Hepatology, 2016. **64**(1): p. 73-84.
- 2. Chalasani, N., et al., *The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.* Hepatology, 2018. **67**(1): p. 328-357.
- 3. Yu, J., et al., *The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background.* Gastroenterology research and practice, 2016. **2016**.
- 4. Tilg, H. and A.R. Moschen, *Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.* Hepatology, 2010. **52**(5): p. 1836-1846.
- 5. Lazo, M., et al., *Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994.* American journal of epidemiology, 2013. **178**(1): p. 38-45.
- 6. Rich, N.E., et al., *Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.* Clin Gastroenterol Hepatol, 2018. **16**(2): p. 198-210.e2.
- 7. Mohanty, S.R., et al., *Influence of ethnicity on histological differences in non-alcoholic fatty liver disease.* Journal of hepatology, 2009. **50**(4): p. 797-804.
- 8. Gabbs, M., et al., *Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.* Advances in Nutrition, 2015. **6**(5): p. 513-540.
- 9. Roy, J., et al., *Non-enzymatic cyclic oxygenated metabolites of omega-3 polyunsaturated fatty acid: Bioactive drugs?* Biochimie, 2016. **120**: p. 56-61.
- 10.Dennis, E.A. and P.C. Norris, *Eicosanoid storm in infection and inflammation.* Nature Reviews Immunology, 2015. **15**(8): p. 511-523.
- 11.Serhan, C.N., *Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.* The FASEB Journal, 2017. **31**(4): p. 1273-1288.
- 12.Mallat, A., et al., *The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.* British journal of pharmacology, 2011. **163**(7): p. 1432-1440.
- 13.Tam, J., et al., *Endocannabinoids in liver disease.* Hepatology, 2011. **53**(1): p. 346-355.
- 14.Puri, P., et al., *A lipidomic analysis of nonalcoholic fatty liver disease.* Hepatology, 2007. **46**(4): p. 1081-1090.
- 15.Chiappini, F., et al., *Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.* Scientific reports, 2017. **7**: p. 46658.
- 16.Puri, P., et al., *The plasma lipidomic signature of nonalcoholic steatohepatitis.* Hepatology, 2009. **50**(6): p. 1827-1838.
- 17.Kalhan, S.C., et al., *Plasma metabolomic profile in nonalcoholic fatty liver disease.* Metabolism-Clinical and Experimental, 2011. **60**(3): p. 404-413.
- 18.Walle, P., et al., *Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.* Metabolism, 2016. **65**(5): p. 655-666.
- 19.Maciejewska, D., et al., *Metabolites of arachidonic acid and linoleic acid in early stages of non-*
- *alcoholic fatty liver disease—A pilot study.* Prostaglandins & other lipid mediators, 2015. **121**: p. 184- 189.
- 20.Loomba, R., et al., *Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.* J Lipid Res, 2015. **56**(1): p. 185-92.

- 21.Feldstein, A.E., et al., *Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.* Journal of lipid research, 2010: p. jlr. M007096.
- 22.Gorden, D.L., et al., *Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.* 491 Journal of lipid research, 2015. **56**(3): p. 722-736.
492 23. Kimberly, W.T., et al., *Metabolite profiling identif*
- 23.Kimberly, W.T., et al., *Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis.* JCI insight, 2017. **2**(9).
- 24.Zelber‐Sagi, S., et al., *Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.* Obesity, 2017. **25**(1): p. 94-101.
- 25.Mazi, T.A., et al., *Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study.* Free Radic Biol Med, 2021. **172**:
- 498 p. 490-502.
499 26. Kleiner, D. I 26.Kleiner, D.E., et al., *Design and validation of a histological scoring system for nonalcoholic fatty liver disease.* Hepatology, 2005. **41**(6): p. 1313-21.
- 27.Bedossa, P., et al., *Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.* Hepatology, 2012. **56**(5): p. 1751-1759.
- 28.Pedersen, T.L., I.J. Gray, and J.W. Newman, *Plasma and serum oxylipin, endocannabinoid, bile acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate format.* Analytica Chimica Acta, 2021. **1143**: p. 189-200.
- 29.Shannon, P., et al., *Cytoscape: a software environment for integrated models of biomolecular interaction networks.* Genome research, 2003. **13**(11): p. 2498-2504.
- 30.Benjamini, Y. and D. Yekutieli, *Quantitative trait loci analysis using the false discovery rate.* Genetics, 2005. **171**(2): p. 783-789.
- 31.Berg, R., *Hoefsloot HCJ van den, Westerhuis JA, Smilde AK, Werf MJ, van der: Centering, scaling, and transformations: improving the biological information content of metabolomics data.* BMC Genomics, 2006. **7**: p. 142.
- 32.Westerhuis, J.A., et al., *Assessment of PLSDA cross validation.* Metabolomics, 2008. **4**(1): p. 81-89.
- 33.Eriksson, L., et al., *Multi-and megavariate data analysis basic principles and applications*. Vol. 1. 2013: Umetrics Academy.
- 34.Murphy, R.A., et al., *Long-chain omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of NHANES 2011–2012.* BMJ open, 2021. **11**(5): p. e043301.
- 35.Steffen, B., et al., *Ethnicity, plasma phospholipid fatty acid composition and inflammatory/endothelial activation biomarkers in the Multi-Ethnic Study of Atherosclerosis (MESA).* European journal of clinical nutrition, 2012. **66**(5): p. 600-605.
- 36.Wood, K.E., et al., *The effect of modifying dietary LA and ALA intakes on omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) status in human adults: a systematic review and commentary.* Prostaglandins, Leukotrienes and Essential Fatty Acids, 2015. **95**: p. 47-55.
- 37.Ramírez-Silva, I., et al., *Fatty acids intake in the Mexican population. Results of the National Nutrition Survey 2006.* Nutrition & metabolism, 2011. **8**(1): p. 33.
- 38.Schaeffer, L., et al., *Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.* Human 528 molecular genetics, 2006. **15**(11): p. 1745-1756.
529 39. Koletzko, B., et al., *Genetic variants of the fatty*
- 39.Koletzko, B., et al., *Genetic variants of the fatty acid desaturase gene cluster predict amounts of red*
- *blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children.* The American journal of clinical nutrition,
- 2011. **93**(1): p. 211-219.

- 40.Wang, L., et al., *Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition.* Hepatology, 2015. **61**(1): p. 119-128.
- 41.Vernekar, M., et al., *Gene polymorphisms of desaturase enzymes of polyunsaturated fatty acid metabolism and adiponutrin and the increased risk of nonalcoholic fatty liver disease.* Meta Gene, 2017. **11**: p. 152-156.
- 42.Yang, C., et al., *Amerind ancestry predicts the impact of FADS genetic variation on omega-3 PUFA deficiency, cardiometabolic and inflammatory risk in Hispanic populations.* medRxiv, 2021.
- 43.Cheng, Q., et al., *Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.* Digestive diseases and sciences, 2013. **58**(10): p. 2895-2902.
- 44.Chen, J., et al., *Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats.* Molecular medicine reports, 2011. **4**(5): p. 811-816.
- 45.Lazic, M., et al., *Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis.* PloS one, 2014. **9**(9): p. e107658.
- 46.López-Parra, M., et al., *Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.* Journal of lipid 550 research, 2008. **49**(12): p. 2513-2523.
551 47.Li, Q., et al., *Plasma Oxylipins Levels*
- 47.Li, Q., et al., *Plasma Oxylipins Levels in Nonalcoholic Fatty Liver Disease.* Digestive Diseases and Sciences, 2020: p. 1-9.
- 48.Warner, J., et al., *Soluble Epoxide Hydrolase Inhibition in Liver Diseases: A Review of Current Research and Knowledge Gaps.* Biology, 2020. **9**(6): p. 124.
- 49.Jourdan, T., et al., *CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.* Diabetes, 2010. **59**(4): p. 926-934.
- 50.Osei-Hyiaman, D., et al., *Hepatic CB 1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.* The Journal of clinical investigation, 2008. **118**(9): p. 3160-3169.
- 51.de Castro, G.S. and P.C. Calder, *Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.* Clinical nutrition, 2018. **37**(1): p. 37-55.
- 52.Musso, G., et al., *Specialized proresolving mediators: enhancing nonalcoholic steatohepatitis and fibrosis resolution.* Trends in pharmacological sciences, 2018. **39**(4): p. 387-401.
- 53.Dufour, J.-F., C. Caussy, and R. Loomba, *Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges.* Gut, 2020. **69**(10): p. 1877-1884.
- 54.Golabi, P., et al., *Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.* Expert review of gastroenterology & hepatology, 2016. **10**(1): p. 63-71.
- 55.Vardarajan, B., et al., *Differences in plasma metabolites related to Alzheimer's disease, APOE ε4 status, and ethnicity.* Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2020. **6**(1): p. e12025.
- 56.Vantaku, V., et al., *Large‐scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.* Cancer, 2019. **125**(6): p. 921-932.
- 57. Musa-Veloso, K., et al., *Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.*
- Nutrition reviews, 2018. **76**(8): p. 581-602.

- 58.Lu, W., et al., *Effects of omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis.*
- 578 Gastroenterology research and practice, 2016. **2016**.
579 59. Hammock, B.D., et al., *Movement to the clinic of sol* 59.Hammock, B.D., et al., *Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative.* Journal of medicinal chemistry, 2021. **64**(4): p. 1856-1872.
- 60.Lazaar, A.L., et al., *Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294,*
- *a novel soluble epoxide hydrolase inhibitor.* British journal of clinical pharmacology, 2016. **81**(5): p. 971-979.

586 **Table 1. Demographic, clinical, and histological characteristics of study subjects in primary analysis**

587 General characteristics of NAFL group in both ethnicities shown as percent (for categorical data) and mean \pm SEM 588 (for nominal data). Comparisons were performed by *t*- test (nominal) or chi-square test (categorical). ALT - alanine

589 aminotransferase; AST - aspartate aminotransferase; CAU - Caucasian; DM -diabetes mellitus; FBG - fasting blood

590 glucose; HbA1c - hemoglobin A1c; HDL - high-density lipoprotein, HIS -Hispanic; LDL - low density lipoprotein;

591 NAFL – Non-alcoholic fatty liver; NAS - the NAFLD Activity Score; TG - triglycerides. (*) NAFL-HIS vs. NAFL-

592 CAU.

593 **Table 2. Demographic, clinical, and histological characteristics of NASH subjects in secondary analysis**

594 General characteristics of subjects included in the secondary analysis shown as percent (for categorical data) and

595 mean ± SEM (for nominal data). Comparisons were performed by *t*- test (nominal) or chi-square test (categorical).

596 BMI - body mass index; CAU - Caucasian; HIS - Hispanic; NASH – Non-alcoholic steatohepatitis; NAS - the

597 NAFLD Activity Score. (*) NAFL-HIS vs. NAFL-CAU.

598

 Figure 1. Differences in plasma PUFA and lipid mediators between NAFL compared to HC in primary cohort. Metabolic network for (a) HIS; (b) CAU illustrating saturated (SFAs), monounsaturated (MUFAs) and polyunsaturated fatty acids (PUFAs), including n-3 and n-6 fatty acids with pathway of oxylipins and polyunsaturated fatty acids (PUFAs), including n-3 and n-6 fatty acids with pathway of oxylipins and endocannabinoids synthesis. Node size represents the fold change of lipids, calculated for each ethnicity separately as (HC - NAFL)/HC. Node's color represents the directionality of metabolite differences: higher in NAFL (red); lower in NAFL (blue); no change (grey). Only fold change for lipids with differences between NAFL vs. HC (*t*-test raw *p* <0.05) and/or with interaction (ethnicity x NAFL) (ANCOVA raw *p* <0.05) are shown. Lipids with interaction (ethnicity x NAFL) (ANCOVA raw *p* <0.05) are marked with a solid circle and lipids. Lipids means and corresponding *p*-values are detailed in Table S3. NAFL (*n* =10 HIS and 8 CAU); HC (*n* =14 HIS and 8 CAU). (b) Venn-Diagram illustrating overlapping and unshared differences in plasma PUFA and lipid mediators between NAFL and HC in both ethnicities. Metabolites with FDR-adjusted *p* <0.2 are shown. Fatty acids are shown in (purple). Other metabolites are colored according to their metabolizing enzymes pathways, lipoxygenase, and 611 autoxidation (red); cytochrome p450 epoxygenase and soluble epoxide hydrolase (blue); cyclooxygenase (green); N-
612 acylphosphatidylethanolamide-phospholipase D (grey); other (black). Fatty acids are described by numb acylphosphatidylethanolamide-phospholipase D (grey); other (black). Fatty acids are described by number of carbons and double bounds of the fatty acyl moiety (i.e., C18:2n6). CAU, Caucasian; HIS, Hispanics; HC, Healthy control; NAFL, Non-alcoholic fatty liver; ADH, alcohol dehydrogenase; AEA, arachidonoyl ethanolamine; AG, arachidonoyl glycerol; Auto, autoxidation; COX, cyclooxygenase; CYP, cytochrome P450; DEA, docosatetraenyl ethanolamide; DGLEA, dihomo-gamma-linolenoyl ethanolamide; DH, dehydrogenase; DHEA, docosahexaenoyl ethanolamide; DiHDoPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHO, dihydroxyoctadecanoic acid; DiHODE, dihydroxyoctadecadienoic acid; DiHOME, dihydroxyoctadecenoic acid; Elov, fatty acid elongase; Ep-KODE, epoxyoxooctadecenoic acid; EpETE, epoxyeicosatetraenoic acid; EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; F2-IsoP, F2 isoprostanes; FAAH, fatty acid amide hydrolase; Fads, fattyaciddesaturase; HDoHE, hydroxydocosahexaenoic acid; 622 HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid;
623 HOTE, hydroxyoctadecatrienoic acid; HpODE, hydroperoxyoctadecadienoic acid; KETE, keto-eicosatetraenoic; HOTE, hydroxyoctadecatrienoic acid; HpODE, hydroperoxyoctadecadienoic acid; KETE, keto-eicosatetraenoic; KODE, keto-octadecadienoic acid; LEA, Linoleyl ethanolamine; LG, linoleoylglycerol; LOX, lipoxygenase; MUFA, Monounsaturated fatty acid; NA-Gly, arachidonylglycine; NAPES, N-acylphosphatidyl ethanolamine- specific; NO-Gly; OEA, oleoyl ethanolamine; OG, oleoylglycerol; PEA, palmitoyl ethanolamine; PGE, prostaglandin E; PGF, prostaglandin F; POEA, palmitoleoyl ethanolamide; PUFA, Polyunsaturated fatty acids; SEA, stearoyl ethanolamide; sEH, soluble epoxide hydrolase; SFA, Saturated fatty acids; TriHOME,

trihydroxyoctadecaenoic acid; TXB, thromboxane.

- cytochrome P450; DEA, docosatetraenyl ethanolamide; DGLEA, dihomo-gamma-linolenoyl ethanolamide; DH,
- dehydrogenase; DHEA, docosahexaenoyl ethanolamide; DiHDoPA, dihydroxydocosapentaenoic acid; DiHETE,
- dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHO, dihydroxyoctadecanoic acid;
- DiHODE, dihydroxyoctadecadienoic acid; DiHOME, dihydroxyoctadecenoic acid; Elov, fatty acid elongase; Ep-
- KODE, epoxyoxooctadecenoic acid; EpETE, epoxyeicosatetraenoic acid; EpODE, epoxyoctadecadienoic acid;
- EpOME, epoxyoctadecenoic acid; F2-IsoP, F2 isoprostanes; FAAH, fatty acid amide hydrolase; Fads,
- fattyaciddesaturase; HDoHE, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE,
- hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; HOTE, hydroxyoctadecatrienoic acid; HpODE,
- hydroperoxyoctadecadienoic acid; KETE, keto-eicosatetraenoic; KODE, keto-octadecadienoic acid; LEA, Linoleyl
- ethanolamine; LG, linoleoylglycerol; LOX, lipoxygenase; MUFA, Monounsaturated fatty acid; NA-Gly,
- arachidonylglycine; NAPES, N-acylphosphatidyl ethanolamine-specific; NOS Nitric oxide synthase; NO-Gly;
- OEA, oleoyl ethanolamine; OG, oleoylglycerol; PEA, palmitoyl ethanolamine; PGE, prostaglandin E; PGF,
- prostaglandin F; PLD- N-acylphosphatidylethanolamide-phospholipase D; POEA, palmitoleoyl ethanolamide;
- PUFA, Polyunsaturated fatty acids; SEA, stearoyl ethanolamide; sEH, soluble epoxide hydrolase; SFA, Saturated
- fatty acids; TriHOME, trihydroxyoctadecaenoic acid; TXB, thromboxane.

658

659 **Figure 3. Supervised multivariate clustering model demonstrating ethnicity specific OXLs profile**

660 **discriminates HIS and CAU with NASH without advanced fibrosis.** Score plot for NASH-HIS (red) vs. NASH-661 CAU (blue) when excluding when excluding stage 3 and 4 fibrosis (*n* = 9 HIS and 13 CAU). Light color represents

662 subjects from primary cohort and dark color represents secondary cohort. The model was performed on all profiled

663 lipids. Lipid mediators are colored according to their metabolizing enzymes pathways, lipoxygenase, and

664 autoxidation (red); cytochrome p450 epoxygenase (brown); and soluble epoxide hydrolase (green); cyclooxygenase

665 (blue); other (black). The model was validated with leave-one-out cross validation (LOOCV). The (Q^2) and (R^2) is

666 0.99 and 0.98, respectively. Details on variable importance into the projection (VIP) scores and cross validation are

667 shown in Table S6. Caucasian; HIS, Hispanics; NASH, Non-alcoholic steatohepatitis; DiHETE,

668 dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHODE, dihydroxyoctadecadienoic acid;

669 DiHOME, dihydroxyoctadecenoic acid; Ep-KODE, epoxyoxooctadecenoic acid; EpETE, epoxyeicosatetraenoic

670 acid; EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; HETE, hydroxyeicosatetraenoic acid;

- 671 HOTE, hydroxyoctadecatrienoic acid; KETE, keto-eicosatetraenoic; KODE, keto-octadecadienoic acid; PGE,
- 672 prostaglandin E; TriHOME, trihydroxyoctadecaenoic acid; TXB, thromboxane.

Supplemental Figure

Figure S1. Principle component analysis (PCA) illustrating outliers before (left) and after (right) data

normalization.

678 **Figure S2. Principle component analysis (PCA) illustrating the unsupervised clustering of samples from**

 Figure S3. Differences in plasma PUFA and lipid mediators between HIS and CAU in lean healthy subjects. Metabolic network illustrating saturated (SFAs), monounsaturated (MUFAs) and polyunsaturated fatty acids (PUFAs), including n-3 and n-6 fatty acids with pathway of oxylipins and endocannabinoids synthesis. Node size represents the fold change of lipids, calculated for each ethnicity separately as (HIS - CAU)/CAU. Node's color represents the directionality of metabolite differences: higher in NAFL (red); lower in NAFL (blue); no change (grey). Only fold change for lipids with differences between HIS vs. CAU (*t*-test raw *p* <0.05) are shown. Lipids means and corresponding *p*-values are detailed in Table S3. (*n* =14 HIS and 8 CAU). Fatty acids are described by number of carbons and double bounds of the fatty acyl moiety (i.e., C18:2n6). CAU, Caucasian; HC, Healthy control; HIS, Hispanics; ADH, alcohol dehydrogenase; AEA, arachidonoyl ethanolamine; AG, arachidonoyl glycerol; Auto, autoxidation; COX, cyclooxygenase; CYP, cytochrome P450; DEA, docosatetraenyl ethanolamide; DGLEA, dihomo-gamma-linolenoyl ethanolamide; DH, dehydrogenase; DHEA, docosahexaenoyl ethanolamide; DiHDoPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHO, dihydroxyoctadecanoic acid; DiHODE, dihydroxyoctadecadienoic acid; DiHOME, dihydroxyoctadecenoic acid; Elov, fatty acid elongase; Ep-KODE, epoxyoxooctadecenoic acid; EpETE, epoxyeicosatetraenoic acid; EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; F2-IsoP, F2 isoprostanes; FAAH, fatty acid amide hydrolase; Fads, fattyaciddesaturase; HDoHE, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; HOTE, hydroxyoctadecatrienoic acid; HpODE, hydroperoxyoctadecadienoic acid; KETE, keto-eicosatetraenoic; KODE, keto-octadecadienoic acid; LEA, Linoleyl ethanolamine; LG, linoleoylglycerol; LOX, lipoxygenase;

- MUFA, Monounsaturated fatty acid; NA-Gly, arachidonylglycine; NAPES, N-acylphosphatidyl ethanolamine-
- specific; NO-Gly; OEA, oleoyl ethanolamine; OG, oleoylglycerol; PEA, palmitoyl ethanolamine; PGE,
- prostaglandin E; PGF, prostaglandin F; POEA, palmitoleoyl ethanolamide; PUFA, Polyunsaturated fatty acids;
- SEA, stearoyl ethanolamide; sEH, soluble epoxide hydrolase; SFA, Saturated fatty acids; TriHOME,
- trihydroxyoctadecaenoic acid; TXB, thromboxane.

Figure S4. Supervised multivariate clustering model demonstrating comparing OXLs profile in HIS and CAU

with NASH and advance fibrosis. Score plot for NASH-HIS vs. NASH-CAU when including stage 3 and 4 (*n* = 12

HIS and 17 CAU). Light color represents subjects from primary cohort and dark color represents secondary cohort.

- The model was performed on all profiled lipids. Lipid mediators are colored according to their metabolizing
- enzymes pathways, lipoxygenase, and autoxidation (red); cytochrome p450 epoxygenase (brown); and soluble
- epoxide hydrolase (green); cyclooxygenase (blue); other (black). The model was validated with leave-one-out cross
- 712 validation (LOOCV). The (Q^2) and (R^2) is 0.62 and 0.72. Details on variable importance into the projection (VIP)
- scores and cross validation are shown in Table S6. CAU, Caucasian; HIS, Hispanics; DiHETE,
- dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHODE, dihydroxyoctadecadienoic acid;
- DiHOME, dihydroxyoctadecenoic acid; EpETE, epoxyeicosatetraenoic acid; EpETrE, epoxyeicosatrienoic acid;
- EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; HETE, hydroxyeicosatetraenoic acid;
- HODE, hydroxyoctadecadienoic acid; HOTE, hydroxyoctadecatrienoic acid; KETE, keto-eicosatetraenoic; KODE,
- keto-octadecadienoic acid; PGE, prostaglandin E; TriHOME, trihydroxyoctadecaenoic acid; TXB, thromboxane.

List of tables

- **Table 1. Demographic, clinical, and histological characteristics of study subjects in primary analysis.** General
- 721 characteristics of NAFL and HC groups in both ethnicities shown as percent (for categorical data) and mean \pm SD (for nominal data). Comparisons were performed by *t*- test (nominal) or chi-square test (categorical). ALT, alanine
- aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; FBG, fasting
-
- blood glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein, low density lipoprotein; NAS, the NAFLD
- 725 Activity Score; TG, triglycerides. ^(a) NAFL-HIS vs. HC-HIS; ^(b) NAFL-CAU vs. HC-CAU; ^(c) NAFL-HIS vs.
- NAFL-CAU.

Table 2. Demographic, clinical, and histological characteristics of NASH subjects in secondary analysis.

- General characteristics of subjects included in the secondary analysis shown as percent (for categorical data) and
- mean ± SEM (for nominal data). Comparisons were performed by *t* test (nominal) or chi-square test (categorical).
- BMI body mass index; CAU Caucasian; HIS Hispanic; NASH Non-alcoholic steatohepatitis; NAS the
- NAFLD Activity Score. (*) NAFL-HIS vs. NAFL-CAU.

Supplemental figure captions

- **Figure S1. Principle component analysis (PCA) illustrating outliers before (left) and after (right) data**
- **normalization.**
- **Figure S2. Principle component analysis (PCA) illustrating the unsupervised clustering of samples from**
- **primary (red) and secondary cohort (green) shown before (left) and after (right) batch correction.**
- **Figure S3. Differences in plasma PUFA and lipid mediators between HIS and CAU in lean healthy subjects.**
- Metabolic network illustrating saturated (SFAs), monounsaturated (MUFAs) and polyunsaturated fatty acids
- (PUFAs), including n-3 and n-6 fatty acids with pathway of oxylipins and endocannabinoids synthesis. Node size
- represents the fold change of lipids, calculated for each ethnicity separately as (HIS CAU)/CAU. Node's color
- represents the directionality of metabolite differences: higher in NAFL (red); lower in NAFL (blue); no change
- (grey). Only fold change for lipids with differences between HIS vs. CAU (*t*-test raw *p* <0.05) are shown. Lipids
- means and corresponding *p*-values are detailed in Table S3. (*n* =14 HIS and 8 CAU). Fatty acids are described by
- number of carbons and double bounds of the fatty acyl moiety (i.e., C18:2n6). CAU, Caucasian; HC, Healthy
- control; HIS, Hispanics; ADH, alcohol dehydrogenase; AEA, arachidonoyl ethanolamine; AG, arachidonoyl
- glycerol; Auto, autoxidation; COX, cyclooxygenase; CYP, cytochrome P450; DEA, docosatetraenyl ethanolamide;
- DGLEA, dihomo-gamma-linolenoyl ethanolamide; DH, dehydrogenase; DHEA, docosahexaenoyl ethanolamide;
- DiHDoPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE,
- dihydroxyeicosatrienoic acid; DiHO, dihydroxyoctadecanoic acid; DiHODE, dihydroxyoctadecadienoic acid;
- DiHOME, dihydroxyoctadecenoic acid; Elov, fatty acid elongase; Ep-KODE, epoxyoxooctadecenoic acid; EpETE,
- epoxyeicosatetraenoic acid; EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; F2-IsoP, F2
- isoprostanes; FAAH, fatty acid amide hydrolase; Fads, fattyaciddesaturase; HDoHE, hydroxydocosahexaenoic acid;
- HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid;
- HOTE, hydroxyoctadecatrienoic acid; HpODE, hydroperoxyoctadecadienoic acid; KETE, keto-eicosatetraenoic;
- KODE, keto-octadecadienoic acid; LEA, Linoleyl ethanolamine; LG, linoleoylglycerol; LOX, lipoxygenase;
- MUFA, Monounsaturated fatty acid; NA-Gly, arachidonylglycine; NAPES, N-acylphosphatidyl ethanolamine-
- specific; NO-Gly; OEA, oleoyl ethanolamine; OG, oleoylglycerol; PEA, palmitoyl ethanolamine; PGE,
- prostaglandin E; PGF, prostaglandin F; POEA, palmitoleoyl ethanolamide; PUFA, Polyunsaturated fatty acids;
- SEA, stearoyl ethanolamide; sEH, soluble epoxide hydrolase; SFA, Saturated fatty acids; TriHOME,
- trihydroxyoctadecaenoic acid; TXB, thromboxane.

Figure S4. Supervised multivariate clustering model demonstrating comparing OXLs profile in HIS and CAU

- **with NASH and advance fibrosis.** Score plot for NASH-HIS vs. NASH-CAU when including stage 3 and 4 (*n* = 12
- HIS and 17 CAU). Light color represents subjects from primary cohort and dark color represents secondary cohort.

- The model was performed on all profiled lipids. Lipid mediators are colored according to their metabolizing
- enzymes pathways, lipoxygenase, and autoxidation (red); cytochrome p450 epoxygenase (brown); and soluble
- epoxide hydrolase (green); cyclooxygenase (blue); other (black). The model was validated with leave-one-out cross
- 767 validation (LOOCV). The (Q^2) and (R^2) is 0.62 and 0.72. Details on variable importance into the projection (VIP)
- scores and cross validation are shown in Table S6. CAU, Caucasian; HIS, Hispanics; DiHETE,
- dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHODE, dihydroxyoctadecadienoic acid;
- DiHOME, dihydroxyoctadecenoic acid; EpETE, epoxyeicosatetraenoic acid; EpETrE, epoxyeicosatrienoic acid;
- EpODE, epoxyoctadecadienoic acid; EpOME, epoxyoctadecenoic acid; HETE, hydroxyeicosatetraenoic acid;
- HODE, hydroxyoctadecadienoic acid; HOTE, hydroxyoctadecatrienoic acid; KETE, keto-eicosatetraenoic; KODE,
- keto-octadecadienoic acid; PGE, prostaglandin E; TriHOME, trihydroxyoctadecaenoic acid; TXB, thromboxane.

Supplemental tables captions

- **Table S1. Details on detected lipid class and identifiers.**
- **Table S2. Targeted quantification data table for comparisons of Hispanic (HIS) and Caucasian (CAU) obese**
- **subjects with Non-alcoholic fatty liver disease (NAFL) vs. lean healthy control (HC).** Comparisons between
- NAFL vs. HC performed separately in each ethnicity. (*n* =10 HIS and 8 CAU); HC (*n* =14 HIS and 8 CAU). Details
- are shown for *p*-values; means (upper-lower 95% mean); fold change (FC); *t*-test and ANCOVA *p*-values for
- individual lipids. Values are rounded to 3 significant figures.
- **Table S3. Demographic, clinical, and histological characteristics of histology-matched subjects.** General
- 783 characteristics of NAFL and HC groups in both ethnicities shown as percent (for categorical data) and mean \pm SEM
- (for nominal data). Comparisons were performed by *t* test (nominal) or chi-square test (categorical). ALT alanine
- aminotransferase; AST aspartate aminotransferase; BMI body mass index; CAU Caucasian; DM -diabetes
- mellitus; FBG fasting blood glucose; HbA1c hemoglobin A1c; HDL high-density lipoprotein, HIS -Hispanic;
- LDL low density lipoprotein; NAFL Non-alcoholic fatty liver; NAS the NAFLD Activity Score; TG,
- triglycerides. *(a)* NAFL-HIS vs. HC-HIS; *(b)* NAFL-CAU vs. HC-CAU; 788 *(c)* NAFL-HIS vs. NAFL-CAU.
- **Table S4. Targeted quantification data table for comparisons of Hispanic (HIS) and Caucasian (CAU) with**
- **Non-alcoholic steatohepatitis (NASH) vs. 0-NASH.** Comparisons between NASH vs. 0-NASH performed
- separately in each ethnicity. NASH (*n* =6 HIS and 3 CAU); 0-NASH (*n* =4 HIS and 5 CAU). Details are shown for
- *p*-values; means (upper-lower 95% mean); fold change (FC); *t*-test and ANCOVA *p*-values for individual lipids.
- Values are rounded to 3 significant figures.

Table S5: Targeted quantification data table for comparisons of Hispanic (HIS) and Caucasian (CAU) with

- **Non-alcoholic steatohepatitis (NASH) in the secondary analysis.** Details on variable importance into the
- projection (VIP) scores and cross validation for multivariate clustering model demonstrating ethnicity specific OXLs
- 797 profile discriminates HIS and CAU with NASH. ^(a) including stage 3 and 4 ($n = 12$ HIS and 17 CAU); ^(b) when
- excluding when excluding stage 3 and 4 (*n* = 9 HIS and 13 CAU). CAU Caucasian; HIS White Hispanic; Non-
- alcoholic steatohepatitis.

Table S6: Pearson's correlation analysis between LOX metabolites and markers of oxidative stress.

- 801 Correlation analysis between alcohols and ketones derived from 5, 12 and 15 LOX with and autoxidative markers,
- F2 isoprostanes and 9-HETE in *(a)* NAFL subjects (examined in primary cohort); 802 *(b)* NASH subjects (examined in
- secondary cohort). CAU Caucasian; HIS White Hispanic; NAFL Non-alcoholic fatty liver; Non-alcoholic
- steatohepatitis.